Clinical Trials

Inclusion Criteria:

• Confirmation of diagnosis.
• Relapsed or relapsed/refractory disease.
• Age ≥ 18 years old.
• ECOG performance status (0-2).
• Life expectancy > 3 months.
• Adequate bone marrow and renal functions.
• QTcF <500 msec.
• Ability to comply with treatment, PK and test schedules.
• NHL only - at least one measurable lesion.

Exclusion Criteria: 

• Active plasma cell leukemia and/or leukemic manifestations of lymphoma.
• Known amyloidosis (MM patients).
• Chronic lymphocytic leukemia and Richter's transformation, and prolymphocytic leukemia (NHL subjects).
• T-cell malignancy.
• Sensory or motor neuropathy ≥ grade 2.
• Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C.
• Ongoing immunosuppressive therapy, including systemic corticosteroids.
• Note: Subjects may be using topical or inhaled corticosteroids. 
• Clinically significant cardiac disease.
• Significant concurrent, uncontrolled medical condition.
• History or clinical signs of meningeal or active CNS involvement.
• Known severe chronic obstructive pulmonary disease or asthma.
• History of significant cerebrovascular disease.
• . Known Human Immunodeficiency Virus seropositivity.
• Positive serology for hepatitis B defined by a positive test for HBsAg.
• Concurrent participation in another therapeutic treatment trial.
• High screening liver function tests.
• Prior treatment with CD74 targeting therapy.
• Patients requiring anti-coagulant therapy